Four percent trisodium citrate as an alternative anticoagulant for maintaining patency of central venous hemodialysis catheters: Case report and discussion

American Journal of Critical Care

Volumn 10, Issue 5, 2001, Pages 351-354

  Michaud, Dominique ^a   Komant, Tracey ^b   Pfefferle, Patrick ^b  

^a LAVAL UNIVERSITY   (Canada)

^b ROYAL ALEXANDRA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CITRIC ACID;

AGED; ARTICLE; CASE REPORT; CENTRAL VENOUS CATHETERIZATION; FEMALE; HOSPITALIZATION; HUMAN; INDWELLING CATHETER; INSTRUMENTATION; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; CATHETERIZATION, CENTRAL VENOUS; CATHETERS, INDWELLING; CITRATES; FEMALE; HOSPITALIZATION; HUMANS; INFUSIONS, INTRAVENOUS; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 0035459437     PISSN: 10623264     EISSN: None     Source Type: Journal    
DOI: 10.4037/ajcc2001.10.5.351     Document Type: Article

References (29)

1. Eby CS. Heparin-induced thrombocytopenia. Clin Lab Sci. 1999;12:365-369.
2. Tollefsen DM, Blinder MA. Heparin. In: Hoffman R, Benz EJ, Sharril SJ, Furie B, Cohen HJ, Silberstein IE, eds. Hematology: Basic Principles and Practice. 2nd ed. New York, NY: Churchill Livingstone; 1995:124-140.
3. Fareed J, Walenga JM, Hoppensteadt DA, et al. Soluble adhesion molecules in the HIT syndrome: pathophysiologic role and therapeutic modulation. Clin Appl Thromb Hemost 1999;5(suppl 1):S38-S44.
4. Warkentin TE, Kelton JG. Heparin and platelets. Hematol Oncol Clin North Am. 1990;4:243-264.
5. Schwab SJ, Harrington JT, Singh A, et al. Vascular access for hemodialysis. Kidney Int. 1999;55:2078-2090.
6. Ashouri OS. Regional sodium citrate anticoagulation in patients with active bleeding undergoing hemodialysis. Uremia Invest. 1985-1986;9:45-51.
7. Ward DM. The approach to anticoagulation in patients treated with extracorporeal therapy in the intensive care unit. Adv Ren Replace Ther. 1997;4:160-173.
8. Boyd LM, Felton SE. Regional citrate anticoagulation: A viable alternative? ANNA J. 1986;13:267-268.
9. Bohler J, Schollmeyer P, Dressel B, Dobos G, Horl WH. Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: dissociation of complement activation and neutropenia from neutrophil degranulation. J Am Soc Nephrol. 1996;7:234-241.
10. Meir-Kriesche HU, Finkel KW, Gitomer JJ, DuBose TD. Unexpected severe hypocalcemia during continuous venovenous hemodialysis with regional citrate anticoagulation. Am J Kidney Dis. 1999;33:1-4.
11. Mehta RL, McDonald BR, Aguilar MM, Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int. 1990;38:976-981.
12. Von Brecht JH, Flanigan MJ, Freeman RM, Lim VS. Regional anticoagulation: hemodialysis with hypertonic trisodium citrate. Am J Kidney Dis. 1986;8:196-201.
13. Breiterman-White R. Sodium citrate use for anticoagulation in hemodialysis. ANNA J. 1995;22:607-609.
14. Dzik WH, Kirkley SA. Citrate toxicity during massive blood transfusion. Transfus Med Rev. 1988;2:76-94.
15. Apsner R, Schwarzenhofer M, Derfler K, Zauner C, Ratheiser K, Kranz A. Impairment of citrate metabolism in acute hepatic failure. Wien Klin Wochenschr. 1997;109:123-127.
16. Jennings ER, Beland AJ, Cope JA, Ellestad MH, Monroe C, Shadle OW. Citrate toxicity and the use of anticoagulant and citrate dextrose blood for extracorporeal circulation. Surg Gynecol Obstet. 1965;120:997-1008.
17. Bunker JP, Dendixen HH, Murphy AJ. Hemodynamic effects of intravenously administered sodium citrate. N Engl J Med. 1962;266:372-377.
18. Kulkarni P, Bhattacharya S, Petros AJ. Torsade de pointes and long QT syndrome following major blood transfusion. Anaesthesia. 1992;47:125-127.
19. Hocken AG, Hurst PL. Citrate anticoagulation in haemodialysis. Nephron. 1987;46:7-10.
20. Ptak J, Novackova L, Stachelova M, Slabik D, Kralova S. Plasma pH and anticoagulant solutions used in the plasmapheresis method of blood collection from donors [in Czech]. Vnitr Lek. 2000;46:111-113.
21. Choi MY, Lee JD, Park IS, et al. Metabolic alkalosis induced by plasmapheresis in a patient with systemic lupus erythematosus. J Korean Med Sci. 1993;8:207-209.
22. Leblanc M, Bosc JY, Paganini EP, Canaud B. Central venous dialysis catheter dysfunction. Adv Ren Replace Ther. 1997;4:377-389.
23. Flanigan MJ, Von Brecht J, Freeman RM, Lim VS. Reducing the hemorrhagic complications of hemodialysis: a controlled comparison of low-dose heparin and citrate anticoagulation. Am J Kidney Dis. 1987;9:147-153.
24. Palsson R, Niles JL. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with high risk of bleeding. Kidney Int. 1999;55:1991-1997.
25. Kutsogiannis DJ, Mayers I, Chin WD, Gibney RT. Regional citrate anticoagulation in continuous venovenous hemodiafiltration. Am J Kidney Dis. 2000;35:802-811.
26. Bayes B, Bonal J, Romero R. Sodium citrate for filling haemodialysis catheters. Nephrol Dial Transplant. 1999;14:2532-2533.
27. Buturovic J, Ponikvar R, Kandus A, Boh M, Klinkmann J, Ivanovich P. Filling hemodialysis catheters in the interdialytic period; heparin versus citrate versus polygeline: a prospective randomized study. Artif Organs. 1998;22:945-947.
28. Food and Drug Administration. FDA issues warning on triCitrasol dialysis catheter anticoagulant. FDA talk paper, April 14, 2000. Available at: http://www.fda.gov/bbs/topics/ANSWERS/ANS01009.html. Accessed April 17, 2001.
29. Cardinal P, Allan J, Pham B, Hindmarsh T, Jones G, Delisle S. The effect of sodium citrate in arterial catheters on acid-base and electrolyte measurements. Crit Care Med. 2000;28:1388-1392.